GEM103 shows potential for dry AMD, geographic atrophy treatment

The phase 1 study of GEM103 and geographic atrophy met all endpoints, according to research presented at the virtual American Academy of Ophthalmology annual meeting.
Arshad M. Khanani, MD, MA, managing partner and director of clinical research, Sierra Eye Associates, clinical associate professor of ophthalmology, University of Nevada, reviewed his findings from the phase 1 single-ascending dose trial.
He reported GEM103 produced extended supraphysiologic levels of complement factor H (CFH) and zero dose-limiting toxicities or treatment-related adverse reactions in patients with dry age-related